Skip to main content

Insulin detemir

Pregnancy with insulin pen

01-10-2023 | Pregnancy | News

EXPECT: Degludec noninferior to detemir in pregnancy for type 1 diabetes

Pregnant women with type 1 diabetes can achieve similar glucose control regardless of whether they use insulin degludec or detemir, show the results of the randomised EXPECT trial.

04-01-2021 | Insulin | News

Long-acting insulin analogs may lower hypoglycemia risk in older people with type 2 diabetes

Older people with type 2 diabetes who initiate treatment with long-acting insulin analogs have a lower risk for severe hypoglycemia than those using neutral protamine Hagedorn insulin, real-world study findings suggest.

08-13-2018 | Insulin degludec | News

Fixed degludec–aspart co-formulation shows promise in pediatric diabetes

The fixed soluble co-formulation of insulin degludec/insulin aspart offers similar glycemic control to insulin detemir when each are combined with mealtime insulin aspart in children with type 1 diabetes, research shows.

07-09-2018 | Insulin | News

Few efficacy and safety differences between long-acting insulins

The results of a network meta-analysis suggest that long-acting insulin analogs have broadly equivalent efficacy and safety in patients with type 2 diabetes, although some might be a little better for preventing nocturnal hypoglycemia.

Insulin pens

07-03-2018 | Insulin | News

NPH insulin may be as good as analogs in type 2 diabetes

Patients with type 2 diabetes in clinical practice have similar outcomes regardless of whether they use long-acting insulin analogs or the cheaper human neutral protamine Hagedorn insulin, say researchers.